Title: Risk factors of active upper gastrointestinal bleeding in patients with COVID-19 infection
and the effectiveness of PPI prophylaxis
Version: 1 Date: 03 Oct 2022
Reviewer's report:
Thank you for the opportunity to review this article. In their paper, the authors have investigated
the risk factors for UGIB in patients hospitalized due to COVID-19 and have found that a higher
GBS and a lack of PPI prophylaxis were significant predictors of UGIB.
The strength of this paper:
·         This topic fits the scope of your journal.
·         It covers a big sample of patients hospitalized with COVID-19
·         They controlled both groups for other established risk factors for COVID-19 (antiplatelets
and anticoagulants).
·         They provided multivariate analysis to validate the identified risk factors
Comments:
·        I disagree with the author's statement that says "To our knowledge, this is the first study
reporting the incidence of only UGIB in patients with COVID-19." There are many reports in
well respected journals that reported the rate of UGIB in patients hospitalized with COVID-19.
·       The findings of this study support the widespread use of PPI prophylaxis in
patients hospitalized with COVID-19. However, many papers investigating PPI use in patients
with COVID-19 have reported worsened outcomes in patients using PPIs due to increased
vulnerability to the effect of high viral loads. The authors should address the contradicting results
that they provide in their discussion.
I have no other particular comment for the authors, I think the article is well-written and
well-structured and provides an interesting insight into the risk factors of UGIB in patients
with COVID-19, but findings must be put in context and discussed compared to similar and
contradicting findings that have been reported in the literature.
Title: Risk factors of active upper gastrointestinal bleeding in patients with COVID-19 infection
and the effectiveness of PPI prophylaxis
Version: 1 Date: 03 Oct 2022
Reviewer's report:
Thank you for the opportunity to review this article. In their paper, the authors have investigated
the risk factors for UGIB in patients hospitalized due to COVID-19 and have found that a higher
GBS and a lack of PPI prophylaxis were significant predictors of UGIB.
The strength of this paper:
·         This topic fits the scope of your journal.
·         It covers a big sample of patients hospitalized with COVID-19
·         They controlled both groups for other established risk factors for COVID-19 (antiplatelets
and anticoagulants).
·         They provided multivariate analysis to validate the identified risk factors
Comments:
·        I disagree with the author's statement that says "To our knowledge, this is the first study
reporting the incidence of only UGIB in patients with COVID-19." There are many reports in
well respected journals that reported the rate of UGIB in patients hospitalized with COVID-19.
·       The findings of this study support the widespread use of PPI prophylaxis in
patients hospitalized with COVID-19. However, many papers investigating PPI use in patients
with COVID-19 have reported worsened outcomes in patients using PPIs due to increased
vulnerability to the effect of high viral loads. The authors should address the contradicting results
that they provide in their discussion.
I have no other particular comment for the authors, I think the article is well-written and
well-structured and provides an interesting insight into the risk factors of UGIB in patients
with COVID-19, but findings must be put in context and discussed compared to similar and
contradicting findings that have been reported in the literature.
Please review this paper.
user
Title: Risk factors of active upper gastrointestinal bleeding in patients with COVID-19 infection
and the effectiveness of PPI prophylaxis
Version: 1 Date: 03 Oct 2022
Reviewer's report:
Thank you for the opportunity to review this article. In their paper, the authors have investigated
the risk factors for UGIB in patients hospitalized due to COVID-19 and have found that a higher
GBS and a lack of PPI prophylaxis were significant predictors of UGIB.
The strength of this paper:
·         This topic fits the scope of your journal.
·         It covers a big sample of patients hospitalized with COVID-19
·         They controlled both groups for other established risk factors for COVID-19 (antiplatelets
and anticoagulants).
·         They provided multivariate analysis to validate the identified risk factors
Comments:
·        I disagree with the author's statement that says "To our knowledge, this is the first study
reporting the incidence of only UGIB in patients with COVID-19." There are many reports in
well respected journals that reported the rate of UGIB in patients hospitalized with COVID-19.
·       The findings of this study support the widespread use of PPI prophylaxis in
patients hospitalized with COVID-19. However, many papers investigating PPI use in patients
with COVID-19 have reported worsened outcomes in patients using PPIs due to increased
vulnerability to the effect of high viral loads. The authors should address the contradicting results
that they provide in their discussion.
I have no other particular comment for the authors, I think the article is well-written and
well-structured and provides an interesting insight into the risk factors of UGIB in patients
with COVID-19, but findings must be put in context and discussed compared to similar and
contradicting findings that have been reported in the literature.
assistant